Alejandra S Guberman

Dr. Alejandra S Guberman

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2015 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
CLCarlos Luzzani
Carlos Luzzani
GNGabriel Neiman
Gabriel Neiman
XGXimena Garate
Ximena Garate
MQMaria Questa
Maria Questa
CSClaudia Solari
Claudia Solari
SMSantiago Gabriel Miriuka
Santiago Gabriel Miriuka
Introduction: Mesenchymal stem cells (MSCs) are a promising source of cells for regenerative therapies. Although they can be isolated easily from several tissues, cell expansion is limited since their properties are lost with successive passages. Hence, pluripotent derived MSCs (PD-MSCs) arise as a suitable alternative for MSC production. Nevertheless, at present, PD-MSC derivation protocols are either expensive or not suitable for clinical purposes. Methods: In this work we present a therapy-grade, inexpensive and simple protocol to derive MSCs from pluripotent stem cells (PSCs) based on the use of platelet lysate (PL) as medium supplement. Results: We showed that the PD-MSCPL expressed multiple MSC markers, including CD90, CD73, CD105, CD166, and CD271, among others. These cells also show multilineage differentiation ability and immunomodulatory effects on pre-stimulated lymphocytes. Thorough characterization of these cells showed that a PD-MSCPL resembles an umbilical cord (UC) MSC and differs from a PSC in surface marker and extracellular matrix proteins and integrin expression. Moreover, the OCT-4 promoter is re-methylated with mesenchymal differentiation comparable with the methylation levels of UC-MSCs and fibroblasts. Lastly, the use of PL-supplemented medium generates significantly more MSCs than the use of fetal bovine serum. Conclusions: This protocol can be used to generate a large amount of PD-MSCs with low cost and is compatible with clinical therapies.

29 May 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AWAriel Waisman
Ariel Waisman
FSFederico Sevlever
Federico Sevlever
MCMartín Elías Costa
Martín Elías Costa
MCMaría Soledad Cosentino
María Soledad Cosentino
SMSantiago G. Miriuka
Santiago G. Miriuka
AGAlejandra S Guberman
Alejandra S Guberman
Mouse embryonic stem cells (mESCs) can be maintained as homogeneous populations in the ground state of pluripotency. Release from this state in minimal conditions allows to obtain cells that resemble those of the early post-implantation epiblast, providing an important developmental model to study cell identity transitions. However, the cell cycle dynamics of mESCs in the ground state and during its dissolution have not been extensively studied. By performing live imaging experiments of mESCs bearing cell cycle reporters, we show here that cells in the pluripotent ground state display a cell cycle structure comparable to the reported for mESCs in serum-based media. Upon release from self-renewal, the cell cycle is rapidly accelerated by a reduction in the length of the G1 phase and of the S/G2/M phases, causing an increased proliferation rate. Analysis of cell lineages indicates that cell cycle variables of sister cells are highly correlated, suggesting the existence of inherited cell cycle regulators from the parental cell. Together with a major morphological reconfiguration upon differentiation, our findings support a correlation between this in vitro model and early embryonic events.

23 March 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PVPaula Verneri
Paula Verneri
CECamila Vazquez Echegaray
Camila Vazquez Echegaray
COCamila Oses
Camila Oses
MSMartin Stortz
Martin Stortz
AGAlejandra S Guberman
Alejandra S Guberman
VLValeria Levi
Valeria Levi
Pluripotency maintenance requires transcription factors (TFs) that induce genes necessary to preserve the undifferentiated state and repress others involved in differentiation. Recent observations support that the heterogeneous distribution of TFs in the nucleus impacts on gene expression. Thus, it is essential to explore how TFs dynamically organize to fully understand their role in transcription regulation. Here, we examine the distribution of pluripotency TFs Oct4 and Sox2 in the nucleus of embryonic stem (ES) cells and inquire whether their organization changes during early differentiation stages preceding their downregulation. Using ES cells expressing Oct4-YPet or Sox2-YPet, we show that Oct4 and Sox2 partition between nucleoplasm and a few chromatin-dense foci which restructure after inducing differentiation by 2i/LIF withdrawal. Fluorescence correlation spectroscopy showed distinct changes in Oct4 and Sox2 dynamics after differentiation induction. Specifically, we detected an impairment of Oct4-chromatin interactions whereas Sox2 only showed slight variations in its short-lived, and probably more unspecific, interactions with chromatin. Our results reveal that differentiation cues trigger early changes of Oct4 and Sox2 nuclear distributions that also include modifications in TF-chromatin interactions. This dynamical reorganization precedes Oct4 and Sox2 downregulation and may contribute to modulate their function at early differentiation stages.

4 July 2019 in BMC Developmental Biology
Verified
Journal Article
Open access
PDF file
JCJesica R. Canizo
Jesica R. Canizo
ARAmada E. Ynsaurralde Rivolta
Amada E. Ynsaurralde Rivolta
CECamila Vazquez Echegaray
Camila Vazquez Echegaray
MSMariana Suvá
Mariana Suvá
VAVirgilia Alberio
Virgilia Alberio
RARamiro Alberio
Ramiro Alberio
The segregation of the hypoblast and the emergence of the pluripotent epiblast mark the final stages of blastocyst formation in mammalian embryos. In bovine embryos the formation of the hypoblast has been partially studied, and evidence shows that MEK signalling plays a limited role in the segregation of this lineage. Here we explored the role of different signalling pathways during lineage segregation in the bovine embryo using immunofluorescence analysis of NANOG and SOX17 as readouts of epiblast and hypoblast, respectively. We show that SOX17 starts to be expressed in 16–32-cell stage embryos, whereas NANOG is first detected from 8-cell stage. SOX17 is first co-expressed with NANOG, but these markers become mutually exclusive by the late blastocyst stage. By assessing the expression kinetics of NANOG/SOX17 we show that inhibition of MEK signalling can eliminate SOX17 expression in bovine blastocysts, without altering NANOG expression. Modulation of WNT, PKC and LIF did not affect NANOG expression in the epiblast when used in combination with the ERK inhibitor. This study shows that SOX17 can be used as a reliable early marker of hypoblast in the bovine, and based on its expression profile we show that the hypoblast segregates in day 7 blastocysts. Furthermore, SOX17 expression is abolished using 1 μM of PD0325901, without affecting the NANOG population in the epiblast. Modulation of WNT, PKC and LIF are not sufficient to support enhanced NANOG expression in the epiblast when combined with ERK inhibitor, indicating that additional signalling pathways should be examined to determine their potential roles in epiblast expansion.

1 March 2019 in Journal of Molecular Biology
Verified
Journal Article
Closed access
MCMaría Soledad Cosentino
María Soledad Cosentino
COCamila Oses
Camila Oses
CECamila Vázquez Echegaray
Camila Vázquez Echegaray
CSClaudia Solari
Claudia Solari
AWAriel Waisman
Ariel Waisman
AGAlejandra S Guberman
Alejandra S Guberman

1 March 2016 in Stem Cell Research
Verified
Journal Article
Open access
MQMaría Questa
María Questa
LRLeonardo Romorini
Leonardo Romorini
CBCarolina Blüguermann
Carolina Blüguermann
CSClaudia María Solari
Claudia María Solari
GNGabriel Neiman
Gabriel Neiman
SMSantiago Gabriel Miriuka
Santiago Gabriel Miriuka
Human foreskin fibroblasts were used to generate the iPSC line iPSC-FH2.1 using the EF1a-hSTEMCCA-loxP vector expressing OCT4, SOX2, c-MYC and KLF4, in 5% O2 culture conditions. Stemness was confirmed, as was pluripotency both in vivo and in vitro, in normoxia and hypoxia. Human Embryonic Stem Cell (hESC) line WA-09 and reprogrammed fibroblast primary culture HFF-FM were used as controls.